1.Date of occurrence of the event:2025/12/08

2.Company name:Zhaoke Ophthalmology

3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):None.

4.Reciprocal shareholding ratios:None.

5.Cause of occurrence:TSH Biopharm and Zhaoke Ophthalmology have partnered to introduce an innovative presbyopiatreatment, BCSA25.

6.Countermeasures:
TSH Biopharm and Zhaoke Ophthalmology (6622.HK) have formed a strategic partnership to introduce BCSA25, an innovative presbyopia treatment currently under review by the U.S. FDA. According to studies, the product demonstrated statistically significant improvement in near vision at all time points within 8 hours.

7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None.